Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker RACD
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | SCHEDULE 13G | RACD Research Alliance Corporation IV | Simon Basseyn | 450,000 | 5.8% | SCHEDULE 13G ↗ |
| Nov 13, 2026 | SCHEDULE 13G | RACD Research Alliance Corporation IV | Alex R. Rosen | 450,000 | 5.8% | SCHEDULE 13G ↗ |
| Nov 13, 2026 | SCHEDULE 13G | RACD Research Alliance Corporation IV | Spruce Street Capital LP | 450,000 | 5.8% | SCHEDULE 13G ↗ |
| Jul 21, 2026 | SCHEDULE 13D | RACD Research Alliance Corporation IV | Matthew Hammond | 1.54M | 17.0% | SCHEDULE 13D ↗ |
| Jul 21, 2026 | SCHEDULE 13D | RACD Research Alliance Corporation IV | Research Alliance Holdings IV LLC | 1.54M | 17.0% | SCHEDULE 13D ↗ |
| Jul 21, 2026 | SCHEDULE 13G | RACD Research Alliance Corporation IV | Ortav Yehudai | 500,000 | 5.5% | SCHEDULE 13G ↗ |
| Jul 21, 2026 | SCHEDULE 13G | RACD Research Alliance Corporation IV | Trails Edge Biotechnology Master Fund, LP | 500,000 | 5.5% | SCHEDULE 13G ↗ |
| Jul 21, 2026 | SCHEDULE 13G | RACD Research Alliance Corporation IV | Trails Edge Capital Partners, LP | 500,000 | 5.5% | SCHEDULE 13G ↗ |
| Jul 20, 2026 | SCHEDULE 13G | RACD Research Alliance Corporation IV | Michael Kramarz | 500,000 | 5.5% | SCHEDULE 13G ↗ |
| Jul 20, 2026 | SCHEDULE 13G | RACD Research Alliance Corporation IV | Robert Egen Atkinson | 500,000 | 5.5% | SCHEDULE 13G ↗ |
| Jul 20, 2026 | SCHEDULE 13G | RACD Research Alliance Corporation IV | Commodore Capital Master LP | 500,000 | 5.5% | SCHEDULE 13G ↗ |
| Jul 20, 2026 | SCHEDULE 13G | RACD Research Alliance Corporation IV | Commodore Capital LP | 500,000 | 5.5% | SCHEDULE 13G ↗ |
| Jul 20, 2026 | SCHEDULE 13G | RACD Research Alliance Corporation IV | Perceptive Life Sciences Master Fund, Ltd. | 700,000 | 7.7% | SCHEDULE 13G ↗ |
| Jul 20, 2026 | SCHEDULE 13G | RACD Research Alliance Corporation IV | Joseph Edelman | 700,000 | 7.7% | SCHEDULE 13G ↗ |
| Jul 20, 2026 | SCHEDULE 13G | RACD Research Alliance Corporation IV | Perceptive Advisors LLC | 700,000 | 7.7% | SCHEDULE 13G ↗ |
| Jul 20, 2026 | SCHEDULE 13G | RACD Research Alliance Corporation IV | Mark N. Lampert | 500,000 | 6.4% | SCHEDULE 13G ↗ |
| Jul 20, 2026 | SCHEDULE 13G | RACD Research Alliance Corporation IV | BVF Inc/Il | 500,000 | 6.4% | SCHEDULE 13G ↗ |
| Jul 20, 2026 | SCHEDULE 13G | RACD Research Alliance Corporation IV | BVF Partners L P/Il | 500,000 | 6.4% | SCHEDULE 13G ↗ |
| Jul 20, 2026 | SCHEDULE 13G | RACD Research Alliance Corporation IV | BVF GP Holdings LLC | 459,176 | 5.9% | SCHEDULE 13G ↗ |
| Jul 20, 2026 | SCHEDULE 13G | RACD Research Alliance Corporation IV | BVF Partners OS Ltd. | 32,968 | 0.4% | SCHEDULE 13G ↗ |
| Jul 20, 2026 | SCHEDULE 13G | RACD Research Alliance Corporation IV | Biotechnology Value Trading Fund OS LP | 32,968 | 0.4% | SCHEDULE 13G ↗ |
| Jul 20, 2026 | SCHEDULE 13G | RACD Research Alliance Corporation IV | BVF II GP LLC | 196,800 | 2.5% | SCHEDULE 13G ↗ |
| Jul 20, 2026 | SCHEDULE 13G | RACD Research Alliance Corporation IV | Biotechnology Value Fund II LP | 196,800 | 2.5% | SCHEDULE 13G ↗ |
| Jul 20, 2026 | SCHEDULE 13G | RACD Research Alliance Corporation IV | BVF I GP LLC | 262,376 | 3.4% | SCHEDULE 13G ↗ |
| Jul 20, 2026 | SCHEDULE 13G | RACD Research Alliance Corporation IV | Biotechnology Value Fund L P | 262,376 | 3.4% | SCHEDULE 13G ↗ |
25 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:36 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances